Clinical Trial Update: ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA [Phase 1, Phase 2]

View source ↗

Summary

Completed Phase 1/2 trial evaluating ImmunoTEP 68Ga-IMP-288 in patients with recurrent HER2-negative breast cancer expressing CEA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• ImmunoTEP 68Ga-IMP-288

Snippet

Sponsor: Nantes University Hospital | Conditions: HER2 Negative Breast Carcinoma Expressing CEA | Phase 1, Phase 2 | Status: COMPLETED